Ask AI
ProCE Banner Activity

Frequently Asked Questions: Expanding the Spectrum of HER2 Positivity in Advanced Breast Cancer With T-DXd

Clinical Thought

Read experts’ answers to healthcare professionals’ questions on the optimal use and management of adverse events with the antibody–drug conjugate T-DXd in patients with HER2-low advanced breast cancer.

Released: February 13, 2023

Expiration: February 12, 2024

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca Pharmaceuticals

Daiichi Sankyo, Inc.

Disclosure

Nadia Harbeck, MD, PhD: consultant: AstraZeneca, Daiichi-Sankyo, Lilly, MDS, Novartis, Pierre Fabre, Pfizer, Roche, Sandoz/Hexal, Seagen; fees for non-CME/CE services: AstraZeneca, Daiichi-Sankyo, Lilly, MDS, Novartis, Pfizer, Pierre Fabre, Roche, Seagen.

Komal Jhaveri, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Blueprint Medicine, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Genentech/Roche, Gilead Sciences, Jounce Therapeutics, Lilly/Loxo Oncology, Menarini/Stemline, Novartis, Olema, Pfizer, Seagen, Sun Pharma, Taiho Oncology; researcher: AstraZeneca, Context Therapeutics, Debio, Genentech/Roche, Gilead Sciences, Lilly/Loxo, Merck, Novartis, Pfizer, Puma Biotech, Zymeworks.

Heather McArthur, MD, MPH: advisor: AstraZeneca, Bristol-Myers Squibb, Crown Bioscience, Daiichi Sankyo, Gilead Sciences, Immunomedics, Lilly, Merck, Pfizer, Puma Biotech, Seagen; researcher (paid to institution): Bristol-Myers Squibb, Merck.

Format

This program is made available online.